Actionable insights straight to your inbox

Healthcare

EQUITIES SNAPSHOT

Get Equities to your inbox how you want it.

Please Select Your Interests

Pharmaceuticals

In Phase 3 trials, a Biogen / Eisai Alzheimer’s drug slowed cognitive decline by 27%.

Contributor Commentary

A year before writing about Freeport, I recommended readers buy shares of Bayer AG. Since pitching the idea, the stock is up 12.19%. And guess what? It's still cheap.